TED.L Regulatory News (TED)

18 Mar 2005 11:13

Tepnel Life Sciences PLC18 March 2005 Tepnel launches next-generation High Throughput ELUCIGENE(TM) assays incorporating Fluorescent ARMS technology Manchester, UK. 17 March 2005: Tepnel Life Sciences' (AIM: TED) announces thelaunch today at the American College of Molecular Genetics Annual Meeting inDallas, of ELUCIGENE CF-HT for rapid, high-throughput cystic fibrosis testing.Developed by Tepnel Diagnostics, ELUCIGENE CF-HT detects 30 of the most commoncausative mutations for cystic fibrosis in Caucasians of European origin,providing clinical testing laboratories with comprehensive and reliable results.These kits have been enhanced with an advanced fluorescent format of theextremely well validated ARMS(TM) technology. When used in a Capillary GeneticAnalyser, this provides an easy-to-use assay with the benefit of a 'tried andtrusted' mutation detection method. ELUCIGENE CF-HT has been specificallydesigned for high-volume laboratories, enabling users to quickly process a largenumber of samples, reducing reporting times and laboratory costs. The application of genetics and DNA testing is rapidly being integrated intoroutine healthcare, resulting in an increasing demand for quality-accredited andvalidated assays. Meeting these requirements, the ELUCIGENE(TM) family of kitsfor in vitro diagnostic use provide laboratories simple and cost effectiveassays for use in genetic screening programs. Industry-leading ELUCIGENE(TM)kits are available for the genetic analysis of human diseases such as cysticfibrosis and cardiovascular disease, as well as nine conditions common toindividuals of Ashkenazi Jewish origin. The Capillary Genetic Analyser has rapidly established itself as the standardinstrument for genetic analysis and is available in many laboratories worldwide.Dedicated ELUCIGENE CF-HT software has been developed for easy data handlingand results reporting. Suitable for busy DNA testing laboratories, ELUCIGENE CF-HT offers a rangeoperational benefits, including: • Simple and accurate ARMS(TM) technology - just amplify and analyse. • Full genotype analysis: wild type and mutant alleles detected • Suitable for diagnostic and screening purposes • Rapid, just 31/2 hours to result • Microtitre plate format, high volume processing • No secondary manipulations required (i.e. hybridisation, enzyme incubation etc.) • Cost-effective, semi-automated process; minimal hands-on time • Available as a CE-marked product for in-vitro diagnostic (IVD) use • Also available as an Analyte Specific Reagent • Meets the ACMG/ACOG requirements for cystic fibrosis screening in the US Pursuant to its commitment to advancing the field of genetic analysis, TepnelDiagnostics is now in the process of developing further ELUCIGENE(TM) kitsenhanced with Fluorescent ARMS technology for other human diseases andconditions. Further information on Fluorescent ARMS and the ELUCIGENE(TM) rangeis available at www.elucigene.com. De Facto CommunicationsRichard Anderson+44 (0) 20 7940 1000 Notes to Editors About Tepnel Life Sciences plcTepnel is a UK-based international life sciences company focused on moleculardiagnostics and research products and services including DNA purification kitsand reagents, scientific services for nucleic acid purification, drug analysis,genotyping and genetically modified foods. Tepnel was founded in 1992 to exploitDNA technology generated at UMIST (University of Manchester Institute of Scienceand Technology) and is quoted on the AIM segment of the London Stock Exchange(AIM: TED). More information on Tepnel can be found at www.tepnel.com. This information is provided by RNS The company news service from the London Stock Exchange